IKUTA Soko    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Journal	Formal name：Journal of neurosurgery Abbreviation：J Neurosurg ISSN code：00223085
Volume, Issue, Page	121(3),pp.543-553
Author and coauthor	ISHIKAWA Eiichi†, MURAGAKI Yoshihiro, YAMAMOTO Tetsuya, MARUYAMA Takashi, TSUBOI Koji, IKUTA Soko, HASHIMOTO Koichi, UEMAE Youji, ISHIHARA Takeshi, MATSUDA Masahide, MATSUTANI Masao, KARASAWA Katsuyuki, NAKAZATO Yoichi, ABE Tatsuya, OHNO Tadao, MATSUMURA Akira
Publication date	2014/09
Summary	Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM). In this paper the authors report on a prospective Phase I/IIa clinical trial of fractionated radiotherapy (FRT) concomitant with TMZ therapy, followed by treatment with autologous formalin-fixed tumor vaccine (AFTV) and TMZ maintenance in patients with newly diagnosed GBM.
DOI	10.3171/2014.5.jns132392
Document No.	24995786